Baird Medical Investment Holdings Limited
BDMDHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeBaird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's. Valued at $14.3M, BDMD is a micro-cap name in its sector. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.
Market Cap
$14.3M
Beta
-1.12
P/E (TTM)
—
P/E (Fwd)
3.18
EPS (TTM)
$-0.54
EPS (Fwd)
$0.14
ROE
-46.0%
ROA
-11.9%
Cash
$397,194
Total Debt
$18.9M
Free CF
$22.4M
52W Change
-68.1%
Annual Financials
Cash vs Debt
Where BDMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BDMD finished 66.41% below its 150-day moving average ($1.31) and 68.12% below its 200-day moving average ($1.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDMD overbought or oversold?
At the October 20, 2026 close, BDMD's RSI(14) was 18.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Baird Medical Investment Holdings Limited carries $18.9M in total debt against $397K in cash reserves — debt is roughly 47.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $22.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -46.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $35.1M (2022) to $22.5M (2025), a 36% decline worth watching.
With a beta below 0.7, Baird Medical Investment Holdings Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Baird Medical Investment Holdings Limited carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing BDMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.